AU2864100A - Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products - Google Patents

Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Info

Publication number
AU2864100A
AU2864100A AU28641/00A AU2864100A AU2864100A AU 2864100 A AU2864100 A AU 2864100A AU 28641/00 A AU28641/00 A AU 28641/00A AU 2864100 A AU2864100 A AU 2864100A AU 2864100 A AU2864100 A AU 2864100A
Authority
AU
Australia
Prior art keywords
methods
therapeutically effective
cultured cells
cell membranes
antineoplastic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28641/00A
Inventor
Sui Xiong Cai
John Drewe
Shailaja Kasibhatla
Ben Y Tseng
Eckard Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Publication of AU2864100A publication Critical patent/AU2864100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU28641/00A 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products Abandoned AU2864100A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11810299P 1999-02-01 1999-02-01
US60118102 1999-02-01
US45459599A 1999-12-07 1999-12-07
US09454595 1999-12-07
PCT/US2000/002329 WO2000045165A1 (en) 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Publications (1)

Publication Number Publication Date
AU2864100A true AU2864100A (en) 2000-08-18

Family

ID=26815975

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28641/00A Abandoned AU2864100A (en) 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Country Status (3)

Country Link
EP (1) EP1151295A4 (en)
AU (1) AU2864100A (en)
WO (1) WO2000045165A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
DE69920473T2 (en) 1998-07-21 2006-02-23 Cytovia, Inc., San Diego NEW FLUORESCENCE DYES AND THEIR APPLICATION IN FLUORESCENCE DETECTION METHODS OF FULL CELLS FOR CASAS, PEPTIDASES, PROTEASES AND OTHER ENZYMES AND THEIR USE
WO2002012545A2 (en) 2000-08-03 2002-02-14 Cytovia, Inc. Method of identifying immunosuppressive agents
KR100545930B1 (en) * 2001-05-11 2006-01-25 우석대학교 산학협력단 Pharmaceutical compositions comprising cellidonin or derivatives thereof
US7253206B2 (en) 2002-02-18 2007-08-07 Sanofi-Aventis Deutschland Gmbh Phenalenone derivatives, processes for preparation and use thereof
DE10206849A1 (en) * 2002-02-18 2005-07-28 Aventis Pharma Deutschland Gmbh Phenalenone derivatives, process for making and using same
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
WO2004002428A2 (en) * 2002-07-01 2004-01-08 Cytovia, Inc. Derivatives of gambogic acid and induce apoptosis
AU2003284081A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Deguelin as a chemopreventive agent for lung cancer
EP1789090A2 (en) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
WO2006028969A1 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using na+/k+ atpase inhibitors
EP1655027A1 (en) * 2004-11-04 2006-05-10 Biofrontera Pharmaceuticals GmbH 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine
JP2009274956A (en) * 2006-08-28 2009-11-26 Univ Nihon Malignant tumor-treating agent originated from neem seed
US20100305068A1 (en) * 2006-11-09 2010-12-02 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
JP2008222603A (en) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research Preventive and therapeutic agent of neurodegenerative disease
EP2139325B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Bithionol as anti-angiogenic agent
WO2010027818A2 (en) * 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CN101869574B (en) * 2010-07-24 2011-12-21 南京大学 Application of uabain for enhancing cellular sensitivity of non-small cell lung cancer (NSCLC)
CN103764659A (en) * 2011-06-15 2014-04-30 生命与大脑有限公司 Glioblastoma inhibiting compounds and their use
CN102675273A (en) * 2012-05-03 2012-09-19 吉林大学 3-aryl-8-allyl-7-hydroxy (methoxyl) coumarin and application in preparation of antitumor drugs
US10976306B2 (en) * 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
AU2015101721A4 (en) * 2015-11-26 2016-01-07 Macau University Of Science And Technology Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer
CN107602445B (en) * 2016-07-12 2020-12-01 中国科学院上海药物研究所 Loperamide derivative and application thereof in preparation of medicine for treating mixed lineage leukemia
KR102600091B1 (en) * 2016-08-24 2023-11-09 (주)아모레퍼시픽 Composition for skin-whitening comprising cytochalasin d
JP7061801B2 (en) 2016-11-15 2022-05-02 学校法人東京理科大学 p53 Degradation Inducing Molecules and Pharmaceutical Compositions
EP3542824A4 (en) 2016-11-15 2020-11-04 Tokyo University of Science Foundation Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
CN108096246B (en) * 2017-03-08 2020-07-14 中国农业科学院饲料研究所 Application of quercetin and aconitine in preparation of medicine for treating cervical cancer and medicine for treating cervical cancer
CN107219201B (en) * 2017-04-20 2019-11-12 浙江工商大学 Utilize the immune rear bullfrog antibody of fluorescence microscope citrinin and affine method
CN112516134B (en) * 2019-09-18 2023-06-06 上海医药集团股份有限公司 Application of hydroxyl-containing compound in preparation of medicines
WO2021067799A1 (en) * 2019-10-02 2021-04-08 The General Hospital Corporation Methods and materials for modulating nrf2 pathway
CA3154468A1 (en) * 2019-10-17 2021-04-22 Chengdu Anticancer Bioscience, Ltd. Benzophenanthridine alkaloids and their methods of use
CN111317734A (en) * 2020-03-27 2020-06-23 广州医科大学附属第二医院 Wnt signal pathway inhibitor and application
CN112545979B (en) * 2021-01-12 2022-07-19 山西省肿瘤研究所 Perfusion gel for preventing postoperative recurrence of bladder cancer and preparation method and application thereof
CN113559110A (en) * 2021-08-27 2021-10-29 上海市第一人民医院 Application of ouabain in preparation of Nrf2 inhibitor and medicine for treating diseases related to abnormal activation of Nrf2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
DE69840928D1 (en) * 1997-05-22 2009-08-06 Burnham Inst DETECTION METHODS FOR REAGENTS REGULATING THE "INHIBITOR DER APOPTOSIS PROTEIN" (IAP) AND THEREFORE ACTUATING CASPASE ACTIVITY
US6270980B1 (en) * 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity

Also Published As

Publication number Publication date
EP1151295A1 (en) 2001-11-07
EP1151295A4 (en) 2005-03-30
WO2000045165A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
AU2864100A (en) Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
AU4965799A (en) Bioreactor and cell culturing processes using the bioreactor
AU5757100A (en) Methods and devices for cell culturing and organ assist systems
AU3914300A (en) Cell culture apparatus and method for culturing cells
AU1644295A (en) Cell culture substrates and methods of use
NZ513598A (en) Immortalized cell lines and methods of making the same
AU6874798A (en) Microelectronic biosensor and method of monitoring cultured cells
AU7280098A (en) Methods of fabricating electrochemical cells
AU4993200A (en) Fuel cell and membrane
AU7950900A (en) Electrode for lithium secondary cell and lithium secondary cell
AU7951000A (en) Electrode for lithium cell and lithium secondary cell
AU7951100A (en) Electrode for lithium secondary cell and lithium secondary cell
AU7951200A (en) Electrode for lithium cell and lithium secondary cell
AU2003249227A1 (en) Methods and systems for extended in vitro culture of neuronal cells
AU5116596A (en) Cell culture method
AU2295201A (en) Spore-like cells and uses thereof
AU8827998A (en) Porcine totipotent cells and method for long-term culture
AU3460195A (en) Method of culturing avian cells and cell line obtained thereby
AU1220599A (en) Method for the production and use of dendritic cells
AU7372900A (en) Electrochemical cell having beaded can and method of forming same
AUPO235996A0 (en) Method of cell culture
AU6746296A (en) Cell culture products
AU6736598A (en) Methods for selecting cells and their uses
AU7625600A (en) Electrochemical cell and cell assembly process
AU5515501A (en) Mammalian cell culture chamber

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase